| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1330 | 2016 |
| Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ... Cancer cell 33 (5), 853-861. e4, 2018 | 827 | 2018 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 738 | 2016 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 693 | 2018 |
| Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Tabernero, F Rojo, E Calvo, H Burris, I Judson, K Hazell, E Martinelli, ... Journal of Clinical Oncology 26 (10), 1603-1610, 2008 | 649 | 2008 |
| CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ... Journal of Clinical Oncology 36 (28), 2836-2844, 2018 | 585 | 2018 |
| Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ... Journal of clinical oncology 33 (30), 3401-3408, 2015 | 399 | 2015 |
| Clinical challenges of immune checkpoint inhibitors M de Miguel, E Calvo Cancer cell 38 (3), 326-333, 2020 | 358 | 2020 |
| Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825-2834, 2019 | 350 | 2019 |
| Principles of oncologic pharmacotherapy CH Takimoto, E Calvo Cancer management: a multidisciplinary approach 11, 1-9, 2008 | 287 | 2008 |
| Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort NE Ready, PA Ott, MD Hellmann, J Zugazagoitia, CL Hann, F de Braud, ... Journal of Thoracic Oncology 15 (3), 426-435, 2020 | 260 | 2020 |
| Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma DA White, P Camus, M Endo, B Escudier, E Calvo, H Akaza, H Uemura, ... American journal of respiratory and critical care medicine 182 (3), 396-403, 2010 | 255 | 2010 |
| First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma J Rodon, MA Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ... Clinical Cancer Research 21 (3), 553-560, 2015 | 250 | 2015 |
| Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a … RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ... The Lancet Oncology 20 (8), 1109-1123, 2019 | 245 | 2019 |
| Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors R Bahleda, A Italiano, C Hierro, A Mita, A Cervantes, N Chan, M Awad, ... Clinical Cancer Research 25 (16), 4888-4897, 2019 | 225 | 2019 |
| Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results P Sharma, A Siefker-Radtke, F de Braud, U Basso, E Calvo, P Bono, ... Journal of Clinical Oncology 37 (19), 1608-1616, 2019 | 217 | 2019 |
| Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label … I Brana, A Calles, PM LoRusso, LK Yee, TA Puchalski, S Seetharam, ... Targeted oncology 10, 111-123, 2015 | 209 | 2015 |
| Phase I study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors KH Jung, P LoRusso, H Burris, M Gordon, YJ Bang, MD Hellmann, ... Clinical Cancer Research 25 (11), 3220-3228, 2019 | 202 | 2019 |
| Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer J Cortes, J Rodriguez, JM Aramendia, E Salgado, A Gurpide, ... Oncology 64 (1), 28-35, 2002 | 186 | 2002 |
| Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors E Calvo, J Baselga Journal of Clinical Oncology 24 (14), 2158-2163, 2006 | 180 | 2006 |
